An experimental oral drug claims to do the work of medications like GLP-1s without losing muscle mass. The medication just went through phase 1 clinical trials. Doctors explain the new medication and ...

George Mycock’s fitness routine had gotten out of hand. The 22-year-old was terrified of putting on body fat but eager to develop more muscle. He tracked his food so thoroughly that he was weighing ...

Nov 24 (Reuters) - (This Nov 24 story has been corrected to fix the pricing for Zolgensma to $2.5 million from $2.1 million in paragraph 4) The U.S. Food and Drug Administration has approved Novartis' ...

Betsy Harris was diagnosed with an extremely rare genetic neuromuscular disorder called Congenital Muscular Dystrophy. Her family is trying to raise money to save her. (Photo: GoFundMe) A GoFundMe ...

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the way for the biotech company to seek US approval. Patients with a type of limb ...

Swiss pharmaceutical giant Novartis has announced a definitive agreement to acquire U.S.-based biotech firm Avidity Biosciences for approximately $12 billion in cash, marking another major step in its ...

Duchenne muscular dystrophy (DMD) is an inherited muscle disorder that causes progressive breakdown of muscle tissue. Symptoms typically begin in early childhood, and most parents and caregivers ...

Thank you to our sponsors, presenters and attendees of our inaugural conference! Although much progress has been made in the understanding of the mechanisms of muscle biology and the development of ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. While Ozempic can be great ...

Myotonic Dystrophy (DM) is a hereditary muscle disorder characterized by progressive muscle weakness, myotonia, and multi-system dysfunction. Based on clinical and genetic features, DM can be ...